David Bearss

David Bearss

Company: Halia Therapeutics

Job title: President and CEO


Targeting the NLRP3 Inflammasome for the Treatment of Alzheimer’s 9:00 am

Learning how persistent NLRP3 inflammasome signaling propagates neuroinflammation in aged brains, and promotes AD pathogenesis and progression Hearing how recent data confirms the essential role of NEK7 in the assembly of NLRP3 complex Discovering how Halia is the first to target NEK7 to block the formation of NLRP3 inflammasome complexRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.